Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 554
Filter
1.
Clin Infect Dis ; 79(Supplement_2): S63-S75, 2024 Sep 20.
Article in English | MEDLINE | ID: mdl-39301670

ABSTRACT

The era of modern antiretroviral therapy (ART) has markedly improved health and survival among persons with human immunodeficiency virus (HIV) (PWH). In the pre-ART era, wasting was associated with HIV disease progression to acquired immunodeficiency syndrome and death. Effective ART has reduced the prevalence and incidence of this pre-ART form of HIV-associated wasting. However, a subgroup of ART-treated virally suppressed PWH continue to lose weight, often accompanied by aging-related comorbidities and/or functional deficits. For this subgroup of patients, the older definition of HIV-associated wasting (HIVAW) cannot and should not be applied. An expert panel comprising the authors of this white paper convened to review the existing definition of HIVAW and to create an updated definition that they termed HIV-associated weight loss, based on clinically defined parameters among contemporary PWH receiving ART. Here, clinical features and laboratory biomarkers associated with HIV-associated weight loss are reviewed and approaches to screening and treatment are considered. Available management approaches, including the use of current US Food and Drug Administration-approved medications for HIVAW and other available therapies are discussed. The expert panel also identified knowledge gaps and provided recommendations for clinicians, payers, and researchers.


Subject(s)
HIV Infections , Weight Loss , Humans , HIV Infections/drug therapy , HIV Infections/complications , Anti-HIV Agents/therapeutic use , HIV Wasting Syndrome/drug therapy , Consensus
2.
AIDS Res Hum Retroviruses ; 40(7): 428-434, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38481376

ABSTRACT

HIV-associated wasting (HIVAW) is an underappreciated AIDS-defining illness, despite highly effective antiretroviral therapy (ART). We (a) assessed the association between incident HIVAW/low weight and all-cause mortality and (b) described virologic outcomes after people with HIV (PWH) experienced HIVAW/low weight while on ART. In the Observational Pharmaco-Epidemiology Research & Analysis (OPERA®) cohort, PWH without prior HIVAW/low weight who were active in care in 2016-2020 were followed through the first of the following censoring events: death, loss to follow-up, or study end (October 31, 2021). HIVAW/low weight was a diagnosis of wasting or low body mass index (BMI)/underweight or a BMI measurement <20 kg/m2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between time-dependent HIVAW/low weight and mortality were estimated with extended Cox regression models. Over a median follow-up of 45 months (interquartile range: 27, 65), there were 4,755 (8%) cases of HIVAW/low weight and 1,354 (2%) deaths among 62,314 PWH. PWH who experienced HIVAW/low weight had a significantly higher risk of death than those who did not (HR: 1.96; 95% CI: 1.68, 2.27) after adjusting for age, race, ethnicity, and changes in viral load (VL) and Veterans Aging Cohort Study Mortality Index scores over follow-up. Among 4,572 PWH on ART at HIVAW/low weight, 68% were suppressed (VL of <200 copies/mL); subsequent virologic failure was uncommon (7%). Among viremic PWH, 70% and 60% achieved suppression and undetectability (VL of <50 copies/mL), respectively, over follow-up. HIVAW remains a challenge for some PWH. Particular attention needs to be paid to HIVAW/low weight and virologic control to restore health and potentially reduce the risk of death.


Subject(s)
HIV Infections , HIV Wasting Syndrome , Humans , Male , Female , Middle Aged , Adult , HIV Wasting Syndrome/epidemiology , HIV Wasting Syndrome/mortality , HIV Infections/mortality , HIV Infections/drug therapy , HIV Infections/complications , Antiretroviral Therapy, Highly Active , Viral Load , Anti-HIV Agents/therapeutic use , Risk Factors , Cohort Studies , Body Mass Index , Incidence
3.
Int J Infect Dis ; 139: 86-91, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38052315

ABSTRACT

OBJECTIVES: Chronic diarrhoea and severe wasting associated with HIV infection were first described in East African patients as slim disease (SD) in 1985. The main histological features are flattening of the villi (villous atrophy) and crypt hyperplasia (elongated crypts), i.e., HIV enteropathy (HIVE). Selective loss of mucosal clusters of differentiation 4 (CD4)+ T helper (Th)17+ lymphocytes is the immunological hallmark of HIVE. This review explores (i) the historical background of HIVE and SD, (ii) the relationship between gut mucosal CD4+ Th17+ and intestinal-resident intra-epithelial gamma delta (IRIE) T lymphocytes in pathogenesis of HIVE, (iii) the role of cytokines in regulation of intestinal epithelial proliferation, and (iv) the role of antiretroviral therapy in HIVE. METHODS: Recent studies have highlighted the role of IRIE T lymphocytes, mostly CD8+, in regulating gut epithelial regeneration. CD4+Th17+ and IRIE T cells are necessary to maintain intestinal barrier integrity and mucosal antimicrobial immune defence. However, the immunological cross-talk between such lymphocyte sub-sets culminating in HIVE is uncertain. We undertook a narrative literature review under the headings 'HIVE', 'SD', and 'Highly active antiretroviral therapy (HAART). Relevant studies were located using the electronic search engines Google Scholar and PubMed from 1984 to 2022. RESULTS: Depletion of Th17+ cells in the lamina propria, attributed to low-level viraemia, is accompanied by concomitant increase in the density of gut mucosal IRIE T lymphocytes in AIDS. The latter express a broad range of cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin-17) and chemokines e.g., keratinocyte growth factor, post exposure to HIV-infected cells. Keratinocyte growth factor induces epithelial proliferation mainly in the crypts, leading to functional immaturity of enterocytes, reduced gut absorptive surface area and malabsorption in animal experiments. Of note, the absence of IRIE T cells is associated with a reduction in epithelial cell turnover. Patients with HIVE receiving early HAART show enhanced expression of mucosal repair genes and improvement of gut symptoms. CONCLUSION: Multiple lines of enquiry suggest HIVE is directly related to HIV infection and is a consequence of perturbations in mucosal CD4+Th17+ and IRIE T lymphocytes. The pathological result is enterocyte immaturity and dysfunction. SD whose main features are malabsorption, diarrhoea and weight loss, is a severe clinical expression of HIVE. A better understanding of immuno-pathogenesis of HIVE opens a window of opportunity for the potential use of immunotherapy in HIV disease and other T cell-mediated enteropathies.


Subject(s)
HIV Enteropathy , HIV Infections , HIV Wasting Syndrome , Animals , Humans , HIV Wasting Syndrome/pathology , Fibroblast Growth Factor 7/therapeutic use , HIV Enteropathy/pathology , Intestinal Mucosa/pathology , Diarrhea , CD4-Positive T-Lymphocytes
4.
Ital J Pediatr ; 47(1): 205, 2021 Oct 11.
Article in English | MEDLINE | ID: mdl-34635139

ABSTRACT

BACKGROUND: Malnutrition is very common in HIV-infected individuals. Even though data from different settings are necessary to tackle it, pieces of evidence are limited especially in the case of the nutritional status of HIV-infected children. Hence, this study aims to assess the nutritional status and associated factors among children on antiretroviral therapy. METHODS: An institutional-based cross-sectional study was conducted among 383 HIV-positive children in Southern Ethiopia. Data were collected using an interviewer-administered questionnaire and anthropometry measurement. Data were coded and entered into Epi-Data Version 3.1 and analyzed using SPSS Version 25. Bi-variable and multi-variable binary logistic regression models were used to identify factors associated with nutritional status and variables with p-values <0.05 in multi-variable logistic regression were considered as statistically significant. RESULTS: The prevalence of wasting among HIV-positive children in Southern Ethiopiaselected Hospitals was 36.3% (95% CI, 31.6-41.0) while stunting on the same study population was 5.5% (95% CI, 3.4-7.8). Rural residence, lack of maternal education, low CD4 counts (< 500), using an unprotected water source, having a non-biological mother and recurrent oral lesion were significantly associated with wasting. Furthermore, history of hospital admission, recurrent oral lesion, low CD4 counts (< 500), advanced WHO clinical stage were statically associated with stunting with p-value < 0.05. CONCLUSION: This study found that the prevalence of under-nutrition among HIV-positive children in Ethiopia was significantly high. Therefore, timely identification and monitoring of nutritional problems should be necessary to enhance the effectiveness of ART treatment and to prevent further related complications.


Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Malnutrition/epidemiology , CD4 Lymphocyte Count , Child , Child, Preschool , Cross-Sectional Studies , Educational Status , Ethiopia/epidemiology , Female , Growth Disorders/epidemiology , HIV Infections/epidemiology , HIV Wasting Syndrome/epidemiology , Humans , Male , Rural Population , Water Supply
5.
Arch Pediatr ; 28(3): 238-241, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33685750

ABSTRACT

OBJECTIVES: This study aimed to describe growth and pubertal development of adolescents with HIV infection under highly active antiretroviral therapy (HAART) in Cameroon. DESIGN: Through an observational study, we included 74 adolescents aged 9-17 years who were taking HAART and had attended two care units in Cameroon for at least 6 months. Weight and height were measured and transferred to 2007 WHO curves for 5- to 19-year-olds. Stunting was defined by a height for age z-score less than -2 standard deviations. Wasting was defined by a BMI z-score for age less than -2 standard deviations. Pubertal development was assessed using Tanner stages. We looked into the association between HIV infection characteristics, HAART regimen, and growth/puberty abnormalities with multivariate analysis. The Mann-Whitney U-test was used to compare median values with a p-value ≤0.05. RESULTS: The median age was 13 (11.2-14.7) years. Stunting affected 44% of the children. Wasting affected 9.7% of the adolescents. The age at onset of puberty was in the normal range in both boys and girls. Adolescents aged 12-14 years (OR 3.4 [95% CI, 1.3-8.8], p=0.012) with a past history of opportunistic infection and taking HAART with protease inhibitors were more likely to have stunting. CONCLUSION: In the Cameroonian setting, growth was mainly affected by stunting, but pubertal development was normal in all patients. This may reflect the benefits of HAART in children with HIV infection.


Subject(s)
Growth Disorders/virology , HIV Infections/complications , Puberty/physiology , Adolescent , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Cameroon , Child , Cross-Sectional Studies , Female , Growth Disorders/diagnosis , Growth Disorders/epidemiology , HIV Infections/drug therapy , HIV Infections/physiopathology , HIV Wasting Syndrome/diagnosis , HIV Wasting Syndrome/epidemiology , Humans , Male , Risk Factors
6.
PLoS One ; 15(9): e0238403, 2020.
Article in English | MEDLINE | ID: mdl-32941443

ABSTRACT

BACKGROUND: Malnutrition on the background of HIV (Human Immunodeficiency Virus) infection is a complex medical condition that carries significant morbidity and mortality for affected children, with greater mortality from SAM (Severe Acute Malnutrition) among HIV-positive children than their HIV-negative peers. HIV-induced immune impairment heightened risk of opportunistic infection and can worsen nutritional status of children. HIV infection often leads to nutritional deficiencies through decreased food intake, mal-absorption and increased utilization and excretion of nutrients, which in turn can hasten death. OBJECTIVE: The aim of this systematic review and meta-analysis was to assess the magnitude of underweight, wasting and stunting among HIV positive children in East Africa. METHODS: The authors systematically reviewed and meta-analyzed studies that assessed the prevalence of underweight, wasting and stunting among HIV positive children in East Africa from PubMed, Cochrane Library, Google Scholar, and Gray Literatures using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guideline. The last search date was December 30/2019. The data was extracted in excel sheet considering country, study design, year of publication, prevalence reported. Then the authors transformed the data to STATA 14 for analysis. Heterogeneity across the studies was assessed by the Q and the I2 test. A weighted inverse variance random-effects model was used to estimate the magnitude of underweight, wasting and stunting. The subgroup analysis was done by country, year of publication, and study design. To examine publication bias, a funnel plot and Egger's regression test were used. RESULTS: For the analysis a total of 22 studies with 22074 patients were used. The pooled prevalence of under-weight, wasting, and stunting among HIV positive children in East Africa was found to be 41.63% (95%CI; 35.69-47.57; I2 = 98.7%; p<0.001), 24.65% (95%CI; 18.34-30.95; I2 = 99.2%; p<0.001), and 49.68% (95%CI; 42.59-56.77; I2 = 99.0%; p<0.001) respectively. The prevalence of under-weight among HIV positive children was found to be 49.67% in Ethiopia followed by 42.00 in Rwanda. It was high among cohort studies (44.87%). Based on the year of publication, the prevalence of under-weight among HIV positive children was found to be 40.88% from studies conducted from January 2008-December 2014, while it was 43.68% from studies conducted from 2015-2019. The prevalence of wasting among HIV positive children was found to be 29.7% in Tanzania followed by 24.94% in Ethiopia. Based on the study design, the prevalence of wasting among HIV positive children was found to be high in cohort studies (31.15%). The prevalence of stunting among HIV positive children was found to be 51.63% in Ethiopia, followed by 48.21% in Uganda. CONCLUSIONS: The results presented above provide evidence of a higher prevalence of under nutrition among HIV positive children in East Africa. Despite the country level variations of child under nutrition in East Africa, still it is high in all aspects compared to the studies from other parts of Africa. It is recommended that further systematic review and meta-analysis need to be conducted on magnitude of malnutrition among HIV positive children in Sub-Saharan Africa as a whole.


Subject(s)
Growth Disorders/epidemiology , Growth Disorders/etiology , HIV Infections/complications , HIV Wasting Syndrome/epidemiology , Thinness/epidemiology , Thinness/etiology , Africa, Eastern/epidemiology , Child , Female , Humans , Male , Prevalence , Severe Acute Malnutrition/epidemiology , Severe Acute Malnutrition/etiology , Severe Acute Malnutrition/mortality
7.
Ginebra; WHO; 2020. 106 p.
Monography in English | BIGG | ID: biblio-1254268

ABSTRACT

The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held on 26 September 2018 included commitments by Member States to four new global targets.3 One of these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018­2022. The approximate breakdown of the target is about 7 million in 2018 and about 8 million in subsequent years. The traditional method for diagnosing TB using a light microscope, developed more than 100 years ago, has in recent years been challenged by several new methods and tools. These methods are based on either the detection of mycobacterial antigens or on the detection of mycobacterial DNA. The novel tools to detect presence of Mycobacterium tuberculosis and resistance to anti-TB drugs call for evidence-based policy recommendations. The World Health Organization (WHO) has published a number of guidelines developed by WHO-convened Guideline Development Groups (GDGs), using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to summarize the evidence and to formulate policy recommendations and accompanying remarks. However, the growing number of published guidelines complicates the overview of recommendations for the intended audience (which includes health care personnel, national TB programmes and policymakers), and WHO recognized the need to consolidate the recommendations into one document. The recommendations in this document have been presented in five guidelines published by WHO between 2016 and 2020, as shown in the box below. Earlier guidelines on diagnostics that were not developed according to the GRADE approach have not been included in this consolidated document


Subject(s)
Humans , Child , Adolescent , Adult , Tuberculosis/diagnosis , Immunologic Tests , Tuberculosis/drug therapy , Drug Resistance, Microbial , HIV Wasting Syndrome/immunology , Antitubercular Agents/therapeutic use
8.
Nutr Diet ; 76(3): 257-262, 2019 07.
Article in English | MEDLINE | ID: mdl-31012256

ABSTRACT

AIM: The Ministry of Health in Malawi has scaled-up antiretroviral therapy (ART) for HIV infection. However, the majority of Malawians heavily depend on maize-based stiff porridge (nsima), a protein-deficient staple, a practice that exacerbates wasting and ultimately compromises the success of ART programming. This pilot study was conducted to evaluate the efficacy of utilising soybean-enriched nsima as a strategy for managing HIV-related wasting among resource-poor people. METHODS: A before and after designed study involving 25 wasted (<18.5 BMI (body mass index)) to normal (18.5-24.9 BMI) HIV-positive rural women (21-40 years) taking ART and provided with soybean-maize flour (20 kg/month for 3 months) prepared from hydrothermally treated soybeans and maize in the ratio of 1:4 (wt/wt). Anthropometry was performed at baseline and every month for the 3-month study period. Paired sample t-tests were used to test for changes in body mass and BMI between baseline and the subsequent months. RESULTS: Statistically significant (P < 0.001) cumulative mean weight gain for the first, second and third month of the study were 1.6, 2.1 and 2.9 kg, respectively. The number of participants with low BMI reduced from 6/25 at baseline to 2/25 after 3 months, and the mean BMI improved from 19.3 to 21.1 kg/m2 . CONCLUSIONS: Nsima prepared from a blend of maize and hydrothermally treated soybeans could feasibly be used to prevent and manage wasting among resource-poor people living with HIV/AIDS in sub-Saharan Africa who rely on maize as a major staple.


Subject(s)
Glycine max , HIV Wasting Syndrome/diet therapy , Zea mays , Adult , Body Mass Index , Female , HIV Infections/drug therapy , Humans , Pilot Projects , Weight Gain
9.
Medwave ; 17(9): e7107, 2017 Dec 22.
Article in Spanish, English | MEDLINE | ID: mdl-29272264

ABSTRACT

INTRODUCTION: Wasting syndrome is a common problem in HIV. It leads to substantive morbidity and mortality. The use of cannabinoids has been suggested as a treatment for weight, but it is not clear whether they are really safe and effective. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified eight systematic reviews including ten studies overall, of which six were randomized trials. We concluded it is not clear whether cannabinoids increase appetite or weight in HIV wasting syndrome because the certainty of the evidence is very low, and they probably lead to frequent adverse effects.


INTRODUCCIÓN: El síndrome de emaciación (wasting) en VIH/SIDA aún permanece como un problema común, constituyéndose como un factor de mortalidad en esta población. Se ha postulado el uso de cannabinoides como tratamiento de la baja de peso secundaria a la infección por VIH, lo que aún es controvertido. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios y preparamos tablas de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos ocho revisiones sistemáticas que en conjunto incluyen 10 estudios primarios, de los cuales, seis son ensayos aleatorizados. Concluimos que no está claro si los cannabinoides aumentan el apetito o incrementan el peso en el síndrome de wasting en pacientes con VIH, y probablemente los efectos adversos son frecuentes.


Subject(s)
Cannabinoids/therapeutic use , HIV Wasting Syndrome/drug therapy , Appetite/drug effects , Body Weight/drug effects , Cannabinoids/adverse effects , Databases, Factual , Humans , Randomized Controlled Trials as Topic , Treatment Outcome
10.
Trop Med Int Health ; 22(10): 1302-1313, 2017 10.
Article in English | MEDLINE | ID: mdl-28712113

ABSTRACT

OBJECTIVES: Low grip strength is a marker of frailty and a risk factor for mortality among HIV patients and other populations. We investigated factors associated with grip strength in malnourished HIV patients at referral to ART, and at 12 weeks and 2-3 years after starting ART. METHODS: The study involved HIV-infected Zambian and Tanzanian participants recruited to the NUSTART trial when malnourished (body mass index <18.5 kg/m2 ) and requiring ART. The relationship of grip strength to nutritional, infectious and demographic factors was assessed by multivariable linear regression at referral for ART (n = 1742) and after 12 weeks (n = 778) and 2-3 years of ART (n = 273). RESULTS: In analyses controlled only for sex, age and height, most nutrition and infection-related variables were associated with grip strength. However, in multivariable analyses, consistent associations were seen for fat-free mass index, mid-upper arm circumference, haemoglobin and systolic blood pressure, and a variable association with fat mass index in men. C-reactive protein and CD4 count had limited independent effects on grip strength, while receiving tuberculosis treatment was associated with weaker grip strength. CONCLUSIONS: In this population of originally malnourished HIV patients, poor grip strength was more strongly and independently associated with nutritional than with infection and inflammation variables. Programmes to improve health and survival of HIV patients should incorporate nutritional assessment and management and could use grip strength as a functional indicator of improving nutrition.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/complications , Hand Strength/physiology , Nutritional Status/physiology , Adolescent , Adult , Anti-HIV Agents/pharmacology , Body Mass Index , C-Reactive Protein/analysis , CD4 Lymphocyte Count , Female , HIV Infections/physiopathology , HIV Wasting Syndrome/complications , HIV Wasting Syndrome/diagnosis , HIV Wasting Syndrome/etiology , Humans , Linear Models , Male , Middle Aged , Multicenter Studies as Topic , Muscle Strength Dynamometer , Prognosis , Randomized Controlled Trials as Topic , Risk Factors , Tanzania , Young Adult , Zambia
11.
J Pediatric Infect Dis Soc ; 6(3): 245-252, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-27481854

ABSTRACT

BACKGROUND: Human immunodeficiency virus (HIV)-infected children are particularly susceptible to acute respiratory infections (ARIs). We determined incidence and cofactors for ARIs in HIV-infected infants receiving antiretroviral therapy (ART). METHODS: Human immunodeficiency virus-infected infants initiated ART at ≤12 months of age and were observed monthly for 2 years in Nairobi. Acute respiratory infection rates and cofactors were determined using Andersen-Gill models, allowing for multiple events per infant. RESULTS: Among 111 HIV-infected infants, median age at ART initiation was 4.5 months. Pre-ART median CD4% was 19%, and 29% had wasting. During 24-months follow-up while on ART, upper respiratory infection (URI) and pneumonia rates were 122.6 and 34.7 per 100 person-years (py), respectively. Infants with higher pre-ART viral load (VL) (plasma HIV ribonucleic acid [RNA] ≥7 log10 copies/mL) had 4.12-fold increased risk of pneumonia (95% confidence interval [CI], 2.17-7.80), and infants with wasting (weight-for-height z-score < -2) had 2.87-fold increased risk (95% CI, 1.56-5.28). Infants with both high pre-ART VL and wasting had a higher pneumonia rate (166.8 per 100 py) than those with only 1 of these risk factors (44.4 per 100 py) or neither (17.0 per 100 py). Infants with exposure to wood fuel had significantly higher risk of URI (hazard ratio [HR] = 1.82; 95% CI, 1.44-2.28) and pneumonia (HR = 3.31; 95% CI, 1.76-6.21). CONCLUSIONS: In early ART-treated HIV-infected infants, higher HIV RNA and wasting before ART were independent risk factors for pneumonia. Wood fuel use was associated with URI and pneumonia. Additional data on air pollution and respiratory outcomes in HIV-infected children may help optimize interventions to improve their lung health.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Wasting Syndrome/epidemiology , Pneumonia/epidemiology , Viremia/epidemiology , Female , HIV Infections/complications , HIV Wasting Syndrome/etiology , Humans , Infant , Kenya , Male , Pneumonia/etiology , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/etiology , Risk Factors , Viremia/etiology
12.
PLoS One ; 11(11): e0165772, 2016.
Article in English | MEDLINE | ID: mdl-27812166

ABSTRACT

BACKGROUND: Pediatric uptake and outcomes in antiretroviral treatment (ART) programmes have lagged behind adult programmes. We describe outcomes from a population-based pediatric ART cohort in rural southern Malawi. METHODS: Data were analyzed on children who initiated ART from October/2003 -September/2011. Demographics and diagnoses were described and survival analyses conducted to assess the impact of age, presenting features at enrolment, and drug selection. RESULTS: The cohort consisted of 2203 children <15 years of age. Age at entry was <1 year for 219 (10%), 1-1.9 years for 343 (16%), 2-4.9 years for 584 (27%), and 5-15 years for 1057 (48%) patients. Initial clinical diagnoses of tuberculosis and wasting were documented for 409 (19%) and 523 (24%) patients, respectively. Median follow-up time was 1.5 years (range 0-8 years), with 3900 patient-years of follow-up. Over the period of observation, 134 patients (6%) died, 1324 (60%) remained in the cohort, 345 (16%) transferred out, and 387 (18%) defaulted. Infants <1 year of age accounted for 19% of deaths, with a 2.7-fold adjusted mortality hazard ratio relative to 5-15 year olds; median time to death was also shorter for infants (60 days) than older children (108 days). Survival analysis demonstrated younger age at ART initiation, more advanced HIV stage, and presence of tuberculosis to each be associated with shorter survival time. Among children <5 years, severe wasting (weight-for-height z-score

Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections , Adolescent , Alkynes , Benzoxazines/therapeutic use , CD4 Lymphocyte Count , Child , Child, Preschool , Cohort Studies , Cyclopropanes , Dideoxynucleotides/therapeutic use , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/mortality , HIV Wasting Syndrome/mortality , Humans , Infant , Lamivudine/therapeutic use , Malawi/epidemiology , Male , Proportional Hazards Models , Retrospective Studies , Rural Population , Stavudine/analogs & derivatives , Stavudine/therapeutic use , Survival Analysis , Tuberculosis, Pulmonary/mortality , Zidovudine/therapeutic use
13.
Ter Arkh ; 88(5): 125-129, 2016.
Article in Russian | MEDLINE | ID: mdl-27458631

ABSTRACT

The review of literature analyzes scientific data on wasting syndrome in HIV-infected patients. It considers its etiology, diagnosis,and therapeutic approaches.


Subject(s)
HIV Wasting Syndrome , HIV Wasting Syndrome/diagnosis , HIV Wasting Syndrome/drug therapy , HIV Wasting Syndrome/etiology , Humans
14.
AIDS ; 30(3): 445-54, 2016 Jan 28.
Article in English | MEDLINE | ID: mdl-26760233

ABSTRACT

BACKGROUND: The long-term consequences of wasting among HIV-infected persons are not known. DESIGN: HIV-infected men surviving ≥2 years based on Kaplan-Meier analysis after a clinical diagnosis or weight trajectory consistent with wasting and with available physical function assessment data [grip strength, gait speed, and quality of life (QoL)] were matched to HIV-infected and uninfected men without wasting. METHODS: Matching criteria at the functional assessment included age, calendar year, and CD4 T-cell count and plasma HIV-1 RNA (HIV-infected only). Multivariable linear regression analyses adjusted for age, cohort, race, hepatitis C status, and number of comorbid illnesses were used to assess the impact of wasting on subsequent physical function. RESULTS: Among 85 HIV-infected men surviving ≥2 years after wasting, we evaluated physical function outcomes compared with 249 HIV-infected and 338 HIV-uninfected men with no historical wasting. In multivariable regression models, HIV-infected men with prior wasting had lower grip strength and poorer physical QoL than HIV-infected men with no wasting (P ≤ 0.03), and poorer physical QoL, but higher mental QoL than HIV-uninfected men (P ≤ 0.05). When controlling for measures of immune suppression (nadir CD4 T-cell count/AIDS, the association between wasting and physical QoL was markedly attenuated, whereas there was minimal impact on the association between wasting and grip strength. CONCLUSIONS: HIV-infected wasting survivors had weaker grip strength compared with HIV-infected persons without wasting; immune suppression was associated only with physical QoL. HIV-infected survivors of wasting may represent a population of adults at increased risk for physical function decline.


Subject(s)
HIV Wasting Syndrome/pathology , Motor Activity , Adult , Humans , Male , Middle Aged , Prospective Studies
15.
J Med Assoc Thai ; 98(10): 1045-55, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26638598

ABSTRACT

Hypogonadism is a common complication among HIV infected patients. The prevalence of hypogonadism is 30 to 50% in HIV infected men with wasting syndrome and 20 to 25% in those without wasting syndrome. HIV infection affects the entire hypothalamus-pituitary-gonadal axis via both direct and indirect effects, which are defined in four categories, 1) direct effect of HIV particles, 2) opportunistic infections, 3) HIV-related malignancy and its treatment, and 4) medications that are used for HIV infection or its opportunistic infection. The association between HIV infection, hypogonadism, and cardiovascular diseases has yet to be determined; however, there are data that HIV infection and its treatment, particularly protease inhibitors, worsened the metabolic profiles, which were surrogate markers of cardiovascular diseases. Considerably more attention should be paid to the diagnosis of hypogonadism in this group particularly because HIV infection increases both sex hormone-binding globulin and total testosterone level. Testosterone replacement shows benefits on mood, body composition, and seems to benefit the metabolic profile in HIV infected men with low body mass index.


Subject(s)
HIV Infections/complications , Hypogonadism/etiology , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Protease Inhibitors/therapeutic use , HIV Wasting Syndrome/etiology , Humans , Hypogonadism/drug therapy , Hypogonadism/epidemiology , Male , Prevalence
16.
Calcif Tissue Int ; 97(6): 634-9, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26253396

ABSTRACT

Foreign body-induced granuloma is an uncommon yet clinically significant cause of hypercalcemia. The molecular mechanisms are uncertain, although extrarenal calcitriol production has been proposed. We describe severe hypercalcemia associated with increased levels of plasma calcitriol in a patient with HIV and local granulomatous reaction 5 years after injection of polymethylmethacrylate (PMMA) as dermal filler for cosmetic body sculpting. Extensive evaluation revealed no identifiable cause of increased calcitriol levels. Nuclear imaging was remarkable for diffuse uptake in the subcutaneous tissues of the buttocks. Subsequent muscle biopsy and immunohistochemical staining showed strong local expression of CYP27B1 within histiocytes surrounding globules of PMMA. This case highlights an unfortunate complication of dermal fillers and shows that inflammatory cells can express high levels of CYP27B1 even without frank granulomas. The growing trend of body contour enhancement using injectable fillers should raise suspicion for this cause of hypercalcemia in clinical practice. Patients with HIV who receive this treatment for lipodystrophy or other cosmetic purposes may have increased susceptibility to hypercalcemia in the setting of underlying chronic inflammation. This may be a concern when changing anti-retroviral therapy, since alterations in levels of HIV viremia may initiate or contribute to worsening hypercalcemia.


Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/biosynthesis , Dermal Fillers/adverse effects , Granuloma, Foreign-Body/complications , HIV Wasting Syndrome/surgery , Hypercalcemia/etiology , Polymethyl Methacrylate/adverse effects , Cosmetic Techniques/adverse effects , Humans , Male , Middle Aged , Muscle, Skeletal/pathology
17.
Med Mal Infect ; 45(5): 149-56, 2015 May.
Article in English | MEDLINE | ID: mdl-25861689

ABSTRACT

More than 90% of the estimated 3.2 million children with HIV worldwide, at the end of 2013, were living in sub-Saharan Africa. The management of these children was still difficult in 2014 despite the progress in access to antiretroviral drugs. A great number of HIV-infected children are not diagnosed at 6 weeks and start antiretroviral treatment late, at an advanced stage of HIV disease complicated by other comorbidities such as malnutrition. Malnutrition is a major problem in the sub-Saharan Africa global population; it is an additional burden for HIV-infected children because they do not respond as well as non-infected children to the usual nutritional care. HIV infection and malnutrition interact, creating a vicious circle. It is important to understand the relationship between these 2 conditions and the effect of antiretroviral treatment on this circle to taking them into account for an optimal management of pediatric HIV. An improved monitoring of growth during follow-up and the introduction of a nutritional support among HIV-infected children, especially at antiretroviral treatment initiation, are important factors that could improve response to antiretroviral treatment and optimize the management of pediatric HIV in resource-limited countries.


Subject(s)
Anti-HIV Agents/therapeutic use , Child Nutrition Disorders/epidemiology , HIV Infections/drug therapy , Infant Nutrition Disorders/epidemiology , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/immunology , AIDS-Related Opportunistic Infections/prevention & control , Adolescent , Africa South of the Sahara/epidemiology , Anemia/etiology , Anthropometry , Child , Child Nutrition Disorders/immunology , Child Nutrition Disorders/therapy , Child, Preschool , Comorbidity , Developing Countries , Dietary Supplements , Disease Progression , Female , Growth Disorders/diagnosis , Growth Disorders/etiology , Growth Disorders/prevention & control , HIV Infections/congenital , HIV Infections/epidemiology , HIV Wasting Syndrome/epidemiology , HIV Wasting Syndrome/immunology , Health Services Needs and Demand , Humans , Immunocompromised Host , Infant , Infant Nutrition Disorders/immunology , Infant Nutrition Disorders/therapy , Infant, Newborn , Male , Nutritional Status , Nutritional Support , Prevalence , Risk
18.
FASEB J ; 29(4): 1165-75, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25466897

ABSTRACT

There are no approved therapies for muscle wasting in children infected with human immunodeficiency virus (HIV), which portends poor disease outcomes. To determine whether a soluble ActRIIb receptor Fc fusion protein (ActRIIB.Fc), a ligand trap for TGF-ß/activin family members including myostatin, can prevent or restore loss of lean body mass and body weight in simian immunodeficiency virus (SIV)-infected juvenile rhesus macaques (Macaca mulatta). Fourteen pair-housed, juvenile male rhesus macaques were inoculated with SIVmac239 and, 4 wk postinoculation (WPI) treated with intramuscular injections of 10 mg ⋅ kg(-1) ⋅ wk(-1) ActRIIB.Fc or saline placebo. Body weight, lean body mass, SIV titers, and somatometric measurements were assessed monthly for 16 wk. Age-matched SIV-infected rhesus macaques were injected with saline. Intervention groups did not differ at baseline. Gains in lean mass were significantly greater in the ActRIIB.Fc group than in the placebo group (P < 0.001). Administration of ActRIIB.Fc was associated with greater gains in body weight (P = 0.01) and upper arm circumference than placebo. Serum CD4(+) T-lymphocyte counts and SIV copy numbers did not differ between groups. Administration of ActRIIB.Fc was associated with higher muscle expression of myostatin than placebo. ActRIIB.Fc effectively blocked and reversed loss of body weight, lean mass, and fat mass in juvenile SIV-infected rhesus macaques.


Subject(s)
Activin Receptors, Type II/therapeutic use , Immunoglobulin Fc Fragments/therapeutic use , Simian Acquired Immunodeficiency Syndrome/therapy , Simian Immunodeficiency Virus , Animals , Disease Models, Animal , HIV Wasting Syndrome/prevention & control , Hematocrit , Humans , Ligands , Macaca mulatta , Male , Muscle, Skeletal/pathology , Myostatin/antagonists & inhibitors , Myostatin/genetics , Myostatin/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Fusion Proteins/therapeutic use , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/physiopathology , Transforming Growth Factor beta/antagonists & inhibitors , Up-Regulation , Weight Gain
19.
Med. interna (Caracas) ; 31(1): 31-43, 2015. tab
Article in Spanish | LILACS | ID: lil-772199

ABSTRACT

La tuberculosis (TB) es un problema de salud pública. Analizar la epidemiologia de la tuberculosis en los últimos 10 años. Se diseñó un estudio de casos, descriptivo y analítico, observacional, transversal y retrospectivo en una muestra no probabilística, que incluye 100% de las historias de pacientes mayores de 14 años de edad, de cualquier sexo, con diagnóstico de TB en cualquiera de sus formas clínicas, atendidos en el Hospital General del Oeste, Dr. José Gregorio Hernández, de Caracas, durante el periodo comprendido entre enero de 2004 y diciembre 2013, divididos en dos grupos de 5 años consecutivos denominados A y B. Se analizaron 475 historias médicas, correspondientes a 241 pacientes del grupo A y 234 del B. La edad promedio del grupo total fue 38,97 ± 15,97 con un predominio del género masculino en 60.6%. La mayor parte de la muestra fueron personas que provienen de Caracas en ambos grupos. El estrato socioeconómico fue predominantemente IV de la clasificación de Graffar y representó el 41% en el grupo A y a 73,9% en el B con diferencia estadísticamente significativa. Se identificaron14, 1% y 19,7% de pacientes con enfermedad relacionada con el VIH en los Grupos A y B. Pocos sujetos tenían enfermedades debilitantes crónicas predisponentes y la más importante fue la desnutrición que duplicó la frecuencia en el grupo B (26,5%) vs (12%) en el A , estadísticamente significativa. La radiología de tórax fue el método más utilizado. En el Grupo A recibieron Prueba Terapéutica 52 pacientes mientras que en grupo B, 70. El grupo representó tuberculosis pulmonar en 71,78% para el grupo A y 68,37% para el B: el resto fue en diversas localizaciones extra pulmonares donde predominaron la pleura y los ganglios. Se cumplió la meta terapéutica en 77,1% de grupo A y 80.36% del grupo B y los restantes en ambos grupos correspondieron al abandono de tratamiento o fallecimiento. La desnutrición fue muy importante en el grupo de estudio reciente y el VIH se mantuvo...


Tuberculosis is a public health problem. To analyze the epidemiology of tuberculosis in the last 10 years. A case study, descriptive and analytical, observational, cross-sectional and retrospective in a non random sample, which includes 100% of the records of patients over 14 years of age, of any gender, diagnosed with TB in any one of its clinical forms, treated in the Hospital Dr. José Gregorio Hernández, Caracas, during the period between January 2004 and December 2013 divided in two groups of 4 consecutive years called A and B. 475 medical records were analyzed corresponding to 241 patients in group A and 234 in B. The average age of the total group was 38.97 ± 15.97 with a predominance of the male gender in 60.6%. The majority of the sample belonged to people coming from Caracas in both groups. Socioeconomic level classification Graffar IV was predominant and accounted for 41% in group A and 73.9% in group B with significant statistical difference. 14.1% and 19.7% of patients were identified with HIV-related in Groups A and B. Few patients had chronic debilitating diseases and malnutrition was the most important and it doubled its frequency in group B (26.5%) vs (12%) with a statistically significant difference. The chest x-ray was the most used method. In Group A, 52 patients received therapeutic test while in group B were 70. The group accounted for pulmonary tuberculosis in 71.78% in group A and 68.37% for the B: the rest were in various extrapulmonary sites where it dominated in pleura and ganglia. The therapeutic goal was fulfilled in 77, 1% of group A and 80, 36% in group B and the rest in both groups corresponded to treatment abandonment or death. Malnutrition was very important in the second study group and HIV remained with similar frequency in both groups


Subject(s)
Humans , Male , Adult , Female , Malnutrition/pathology , HIV , HIV Wasting Syndrome/epidemiology , HIV Wasting Syndrome/pathology , Tuberculosis/epidemiology , Internal Medicine
20.
Pan Afr Med J ; 18: 77, 2014.
Article in English | MEDLINE | ID: mdl-25400844

ABSTRACT

INTRODUCTION: Case control studies that assess the burden and factors associated with undernutrition and anaemia among HAART naïve HIV infected children in Nigeria is very sparse. This will help to formulate nutritional programs among these children. METHODS: Seventy HAART naive HIV infected children aged 18 months and above were as well as seventy age and sex matched HIV negative children were recruited from August 2007 to January 2009 at Paediatric Clinic of Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria. Their bio data, WHO clinical stage, anthropometric measurements, haematocrit, serum albumin and CD4 counts were taken with other parameters according to a study proforma. RESULTS: The prevalence of stunting, underweight and wasting among the HIV infected subjects were 48. 6%,58. 6% and 31. 4% respectively which as significantly higher than 28. 1%, 7. 1% and 28. 1% among the HIV negative controls. 20. 1% of the HIV infected children were marasmic compared to 2. 3% of the controls. Triple anthropometric failure was found in 7. 1% of the subjects as compared to none among the controls. Anaemia is significantly more prevalent among the subjects than the controls (70. 0% vs 31. 4%; p<0. 001). The prevalence of anaemia was higher in the HIV infected subjects with undernutrition. Low socioeconomic status, hypoalbuminemia and severe immunosuppression are significantly associated with higher undernutrition prevalence. CONCLUSION: Several years after availability of HAART, undernutrition and anaemia remain widely prevalent among newly presenting HAART naïve HIV infected Nigerian children. Nutritional supplementation and evaluation for anaemia still need close attention in the management of these children.


Subject(s)
Anemia/epidemiology , HIV Infections/epidemiology , Malnutrition/epidemiology , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Case-Control Studies , Child , Child, Preschool , Comorbidity , Cross-Sectional Studies , Developing Countries , Female , HIV Wasting Syndrome/epidemiology , Health Services Accessibility , Hospitals, University/statistics & numerical data , Humans , Hypoalbuminemia/epidemiology , Male , Nigeria/epidemiology , Outpatients/statistics & numerical data , Poverty , Prevalence , Protein-Energy Malnutrition/epidemiology , Socioeconomic Factors , Thinness/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL